Does Argus HQ track new FDA actions for Fujifilm Diosynth Biotechnologies USA Inc. automatically?

Yes. Argus HQ ingests FDA sources daily, including FDA warning letters, recalls, drug and biologic approvals, and Form 483 inspection observations. When a new FDA action linked to Fujifilm Diosynth Biotechnologies USA Inc. is observed, this page's event count and history update automatically.

How many FDA actions does Argus HQ track for Fujifilm Diosynth Biotechnologies USA Inc.?

1 total: 0 warning letters, 0 recalls, 0 approval records, and 1 Form 483 inspection citation.

What is the most recent FDA action on file for Fujifilm Diosynth Biotechnologies USA Inc.?

March 27, 2026. Argus HQ ingests new FDA enforcement records daily.

Is this FDA enforcement data for Fujifilm Diosynth Biotechnologies USA Inc. official?

Every record links directly to its primary FDA.gov source. Argus HQ aggregates and structures public FDA data; the verbatim FDA record is always the source of truth.

Fujifilm Diosynth Biotechnologies USA Inc. — FDA Compliance Timeline

Here's the summary: Argus HQ has recorded 1 FDA events for Fujifilm Diosynth Biotechnologies USA Inc.: 0 warning letters, 0 recalls, 0 approvals, and 1 inspection 483 observations. These events span from 2026-03-27 to 2026-03-27. The most severe rating Argus HQ has assigned across this history is "high". Argus HQ ingests these records directly from FDA's own public enforcement and approval databases rather than from company disclosures. This page reflects only the FDA event types Argus HQ currently tracks -- FDA Warning Letters, recalls, drug and biologic approvals, and Form 483 inspection observations -- and will update automatically as new FDA records are observed. Argus HQ ingests these records directly from FDA's own public enforcement and approval databases rather than from company disclosures.

FDA action counts

Total FDA actions	1
Warning letters	0
Recalls	0
Approval records	0
Form 483 inspection citations	1
Most recent action	March 27, 2026

Enforcement history

On 2026-03-27, Argus HQ recorded an FDA Form 483 inspection citation for Fujifilm Diosynth Biotechnologies USA Inc., rated "high" severity in Argus HQ's classification: Fujifilm Diosynth Biotechnologies USA Inc. -- FDA 483: 1 observation (2026-03-27). Argus HQ ingests these records directly from FDA's own public enforcement and approval databases rather than from company disclosures. This page reflects only the FDA event types Argus HQ currently tracks -- FDA Warning Letters, recalls, drug and biologic approvals, and Form 483 inspection observations -- and will update automatically as new FDA records are observed. Argus HQ ingests these records directly from FDA's own public enforcement and approval databases rather than from company disclosures. This page reflects only the FDA event types Argus HQ currently tracks -- FDA Warning Letters, recalls, drug and biologic approvals, and Form 483 inspection observations -- and will update automatically as new FDA records are observed. Argus HQ ingests these records directly from FDA's own public enforcement and approval databases rather than from company disclosures. This page reflects only the FDA event types Argus HQ currently tracks -- FDA Warning Letters, recalls, drug and biologic approvals, and Form 483 inspection observations -- and will update automatically as new FDA records are observed. Argus HQ ingests these records directly from FDA's own public enforcement and approval databases rather than from company disclosures. This page reflects only the FDA event types Argus HQ currently tracks -- FDA Warning Letters, recalls, drug and biologic approvals, and Form 483 inspection observations -- and will update automatically as new FDA records are observed.

Risk pattern analysis

Argus HQ analysis — not an FDA finding

This section is Argus HQ analysis, not an FDA finding. Fujifilm Diosynth Biotechnologies USA Inc. has 1 FDA event on file. A pattern across multiple FDA touchpoints does not by itself establish that any specific product currently poses a risk; it reflects only the frequency of FDA engagement with this company as recorded in Argus HQ's database. Argus HQ ingests these records directly from FDA's own public enforcement and approval databases rather than from company disclosures. This page reflects only the FDA event types Argus HQ currently tracks -- FDA Warning Letters, recalls, drug and biologic approvals, and Form 483 inspection observations -- and will update automatically as new FDA records are observed. Argus HQ does not independently verify FDA's underlying findings; this page summarizes what FDA has published and links back to the original FDA source for each event. Argus HQ ingests these records directly from FDA's own public enforcement and approval databases rather than from company disclosures.

Frequently asked questions

Does Argus HQ track new FDA actions for Fujifilm Diosynth Biotechnologies USA Inc. automatically?: Yes. Argus HQ ingests FDA sources daily, including FDA warning letters, recalls, drug and biologic approvals, and Form 483 inspection observations. When a new FDA action linked to Fujifilm Diosynth Biotechnologies USA Inc. is observed, this page's event count and history update automatically.
How many FDA actions does Argus HQ track for Fujifilm Diosynth Biotechnologies USA Inc.?: 1 total: 0 warning letters, 0 recalls, 0 approval records, and 1 Form 483 inspection citation.
What is the most recent FDA action on file for Fujifilm Diosynth Biotechnologies USA Inc.?: March 27, 2026. Argus HQ ingests new FDA enforcement records daily.
Is this FDA enforcement data for Fujifilm Diosynth Biotechnologies USA Inc. official?: Every record links directly to its primary FDA.gov source. Argus HQ aggregates and structures public FDA data; the verbatim FDA record is always the source of truth.

Every FDA action tied to this company, the week it happens.

Free weekly briefing. Real-time alerts on paid plans.

Fujifilm Diosynth Biotechnologies USA Inc. -- FDA 483: 1 observation (2026-03-27) →

Compare with

Two different companies merged onto this page by mistake? Or a name variant missing? Tell us — corrections@argushq.ai

Compiled by Argus HQ Research from FDA primary sources · Reviewed by Andy Gaber, Founder

Cite this record

Reusing this data in reporting or research? Here’s a ready-made citation.

APA

Argus HQ Research (2026). Fujifilm Diosynth Biotechnologies USA Inc. — FDA Compliance Timeline. Digital Empire LLC. Retrieved from https://argushq.ai/company/fujifilm-diosynth-biotechnologies-usa-inc

MLA

"Fujifilm Diosynth Biotechnologies USA Inc. — FDA Compliance Timeline." Argus HQ Research, Digital Empire LLC, 2026, argushq.ai/company/fujifilm-diosynth-biotechnologies-usa-inc.

Chicago

Argus HQ Research. "Fujifilm Diosynth Biotechnologies USA Inc. — FDA Compliance Timeline." Digital Empire LLC. Accessed July 13, 2026. https://argushq.ai/company/fujifilm-diosynth-biotechnologies-usa-inc.

BibTeX

@misc{argushq_argushq_ai_company_fujifilm_diosynth_biotechnologies_usa_inc_2026,
  title = {Fujifilm Diosynth Biotechnologies USA Inc. — FDA Compliance Timeline},
  author = {{Argus HQ Research}},
  year = {2026},
  publisher = {Digital Empire LLC},
  url = {https://argushq.ai/company/fujifilm-diosynth-biotechnologies-usa-inc},
  note = {Accessed: July 13, 2026}
}

Source: FDA.gov (aggregated across Warning Letters, Recalls, Approvals, Form 483s) ↗